enow.com Web Search

  1. Ads

    related to: unprovoked dvt apixaban treatment cost comparison chart by year list

Search results

  1. Results from the WOW.Com Content Network
  2. Direct factor Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

    The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [3] [14] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [15]

  3. Discovery and development of direct Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Discovery_and_development...

    Indication for Xa inhibitors is preventing deep vein thrombosis (DVT) which can lead to pulmonary embolism. It is also used to treat atrial fibrillation to lower the risk of stroke caused by a blood clot. Another indication is a prophylactic treatment for blood clotting due to atherosclerosis.

  4. Apixaban - Wikipedia

    en.wikipedia.org/wiki/Apixaban

    [12] [27] In March 2014, it was approved for the additional indication of preventing deep vein thrombosis and pulmonary embolism in people who have recently undergone knee or hip replacement. [28] [29] In August 2014, the FDA approved apixaban for the additional indication of the treatment of recurring deep vein thrombosis and pulmonary embolism.

  5. ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A ...

    www.aol.com/news/2012-12-08-eliquis-apixaban...

    AMPLIFY-EXT (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment), a randomized, double-blind, multicenter trial ...

  6. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the ... - AOL

    www.aol.com/news/2013-01-02-us-fda-approves...

    U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...

  7. ELIQUIS® (apixaban) Demonstrates Consistent Reductions in ...

    www.aol.com/news/2012-10-01-eliquis-apixaban...

    ELIQUIS ® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at ...

  8. Medication costs - Wikipedia

    en.wikipedia.org/wiki/Medication_costs

    Medication costs can be the selling price from the manufacturer, that price together with shipping, the wholesale price, the retail price, and the dispensed price. [3]The dispensed price or prescription cost is defined as a cost which the patient has to pay to get medicines or treatments which are written as directions on prescription by a prescribers. [4]

  9. Cost of drug development - Wikipedia

    en.wikipedia.org/wiki/Cost_of_drug_development

    In an analysis of the drug development costs for 98 companies over a decade, the average cost per drug developed and approved by a single-drug company was $350 million. [3] But for companies that approved between eight and 13 drugs over 10 years, the cost per drug went as high as $5.5 billion. [3]

  1. Ads

    related to: unprovoked dvt apixaban treatment cost comparison chart by year list